EU Panel Recommends AstraZeneca Drug Baxfendy for Uncontrolled Hypertension

The European Medicines Agency’s medicines committee has recommended Baxfendy (baxdrostat), AstraZeneca’s hypertension drug, for EU approval for adults whose blood pressure remains uncontrolled despite taking at least two medicines. The recommendation is based on two Phase III trials that found meaningful reductions in blood pressure among patients with uncontrolled or resistant hypertension. If the European Commission grants marketing authorization, Baxfendy would be the EU’s first aldosterone synthase inhibitor, a drug that lowers blood pressure by blocking aldosterone. The committee’s opinion is not final approval; the drug is already approved in the United States and other countries, with applications under review in Japan and China.